Literature DB >> 7506222

Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary.

G Ueda1, M Sawada, H Ogawa, O Tanizawa, M Tsujimoto.   

Abstract

Mucinous adenocarcinomas of the ovary were studied immunohistochemically for cytokeratins 7 and 18, either to determine whether the ovarian tumor was primary or a metastasis or to establish the histogenetic origin of the tumor. Primary ovarian tumors were strongly positive for both cytokeratins, while ovarian metastases from colonic cancers were negative for cytokeratin 7, as were the colonic cancers. Three of four ovarian tumors complicated by pseudomyxoma peritonei were negative for cytokeratin 7, indicating appendiceal origin. Two of seven mucinous tumors associated with dermoid cysts were negative for cytokeratin 7, suggesting gastrointestinal origin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506222     DOI: 10.1006/gyno.1993.1276

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Immunophenotypings of malignant epithelial mesothelioma and their roles in the differential diagnosis.

Authors:  Qiurong Ruan; Yuchang Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

2.  The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells.

Authors:  E B van Dorst; G N van Muijen; S V Litvinov; G J Fleuren
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

Review 3.  Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

4.  Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.

Authors:  J H Lagendijk; H Mullink; P J van Diest; G A Meijer; C J Meijer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

5.  The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.

Authors:  Mi Jin Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

6.  PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

Authors:  D Ates Ozdemir; A Usubutun
Journal:  Pathol Oncol Res       Date:  2016-01-21       Impact factor: 3.201

7.  Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.

Authors:  T Yanagibashi; I Gorai; T Nakazawa; E Miyagi; F Hirahara; H Kitamura; H Minaguchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary.

Authors:  Divya Kriplani; Mandakini M Patel
Journal:  South Asian J Cancer       Date:  2013-10

9.  Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors.

Authors:  Anne Menz; Timo Weitbrecht; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Christian Bernreuther; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Ronald Simon
Journal:  Mol Med       Date:  2021-02-15       Impact factor: 6.354

Review 10.  Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

Authors:  Pavel Dundr; Naveena Singh; Barbora Nožičková; Kristýna Němejcová; Michaela Bártů; Ivana Stružinská
Journal:  Diagn Pathol       Date:  2021-03-11       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.